We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




A New Rapid Chlamydia Test Suitable for Clinical Labs and POC Use

By LabMedica International staff writers
Posted on 25 Dec 2013
A new rapid assay for Chlamydia trachomatis based on a state-of-the-art nucleic acid amplification technique detects as few as 5 to 12 pathogens per test within 20 minutes directly from urine samples without DNA purification.

Chlamydia trachomatis is the most common sexually transmitted human pathogen. More...
Infections caused by this organism are a major public health concern because of the potential severe long-term consequences, including an increased risk of ectopic pregnancy, chronic pelvic pain, and infertility. However, approximately two-thirds of women with the infection experience minimal or no symptoms and therefore often go undiagnosed.

To date, several point-of-care tests have been developed for detection of C. trachomatis. Although many of them are fast and specific, they demonstrate only 10% to 40% sensitivity, which is inadequate for large-scale applications.

Investigators at Stockholm University (Sweden) and their colleagues at the University of Tartu (Estonia) have developed an improved test for the detection of C. trachomatis using recombinase polymerase amplification (RPA), a nucleic acid amplification technique that is based on the in vitro synthesis of many copies of DNA or RNA from one original template. The new assay amplifies nucleotide fragments of the C. trachomatis CDS2 gene from urine samples. The assay does not require purification of total DNA from the urine sample. Heating for five minutes at 90 °C is sufficient to release enough of the amplification target to determine whether the pathogen is present. While urine contains polymerase chain reaction (PCR) inhibitors, up to five microliters can be tested without affecting sensitivity of the RPA.

The investigators used the RPA assay to analyze urine samples from 70 patients (51 females and 19 males) attending a sexual health clinic in Estonia. The samples were tested in parallel with RPA and with the Roche (Basel, Switzerland) Cobas Amplicor C. trachomatis assay. Results revealed that 58 samples were negative in both assays (100% specificity). Twelve of the samples tested positive using the Roche assay. Of these, 10 tested positive and two tested negative in the RPA reaction. Based on these results, the clinical sensitivity of the RPA assay can be estimated at 83%.

"The alarmingly poor performance of the available POC tests for C. trachomatis has limited their wider use, and there is a clear requirement for more sensitive and cost-effective diagnostic platforms. Hence, the need for an applicable on-site test that offers reasonably sensitive detection," said senior author Dr. Ülo Langel, professor of molecular biotechnology at the University of Tartu and professor of neurochemistry at Stockholm University. "The [RPA] assay enables highly specific C. trachomatis detection with sensitivity levels significantly improved compared to currently available C. trachomatis POC assays."

The study was published in the January 2014 issue of the Journal of Molecular Diagnostics.

Related Links:

Stockholm University
University of Tartu
Roche



Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.